IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#786
Positioning
Market Dominance
Manufacturing
Measuring And Control Equipment
$14.1B
Francis A. deSouza
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and Asia-Pacific region.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = ILMN ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ILMN ILLUMINA, INC. | 59 | 73 | 73 | 60 | 14.7x | 13.4x | 44.8% | 18.4% | 67.0% | 31.4% | 28.5% | -2.5% | 0.0% | 144.0x | $14.1B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
ILLUMINA, INC. (ILMN) receives a "Hold" rating with a composite score of 59.0/100. It ranks #786 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Headcount
11.5K
HQ Base
San Diego, California
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ILMN.
View All RatingsROIC 59.8% vs WACC 8.9% (spread +50.9%)
GM 67% vs sector 44%, OM 31% vs sector 3%
Capital turnover 4.61x, R&D intensity 22.3%
Rev growth -3%, 10yr history
Interest coverage 32.3x, Net debt/EBITDA 1.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate ILLUMINA, INC. (ILMN) as a Hold with a composite score of 59.0/100 at a current price of $122.90. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
ILLUMINA, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 59.0/100 places it at rank #786 in our full universe.
The near-term outlook is constructive, with revenue growing at -3% and momentum in the 60th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
Wide
Medium
Standard
Undervalued
Gross margins of 67% signal strong pricing power.
Returns on equity of 44.8% exceed cost of capital.
Value factor score of 73 suggests attractive pricing.
Leverage of 144% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
ILLUMINA, INC. represents a hold based on multi-factor quantitative performance.
Our model assigns ILLUMINA, INC. a Hold rating, with a composite score of 59.0/100 and 3 out of 5 stars. Ranked #786 of 7,333 stocks, ILMN presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
ILMN earns a quality score of 73/100, indicating above-average business quality. The company reports a return on equity of 44.8% (sector avg: -1.9%), gross margins of 67.0% (sector avg: 44.1%), net margins of 28.5% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
ILMN carries a solid value score of 73/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 14.74x, an EV/EBITDA of 13.37x, a P/B ratio of 6.61x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
With an investment score of 48/100, ILMN exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of -2.5% vs. a sector average of 6.7% and a return on assets of 18.4% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
ILMN demonstrates moderate momentum with a score of 60/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -2.5% year-over-year, while a beta of 1.04 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
With a stability score of 60/100, ILMN exhibits average financial resilience. Key stability metrics include a beta of 1.04 and a debt-to-equity ratio of 144.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
ILLUMINA, INC.'s short interest score of 30/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 144.00x). At $14.1B (large-cap), ILMN carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
ILLUMINA, INC. is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #786 of 7,333 overall (89th percentile). Key comparisons include ROE of 44.8% exceeding the -1.9% sector median and operating margins of 31.4% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ILMN currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Value (73) vs Short Int. (30) — closing this gap could shift the rating.
EV/EBITDA 17% ABOVE SECTOR MEDIAN
ROE 2460% BELOW SECTOR MEDIAN
Gross Margin 52% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter 2025 revenue from Continuing Operations of $23.8 million; Full Year 2025 revenue of $85.3 millionFully operationalized over $40 million in previously announced annualized cost savings supporting path to positive adjusted EBITDA and adjusted cash flow
Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.
The Cancer Diagnostics Market is set to grow from USD 197.7 billion in 2025 to USD 345.57 billion by 2033, driven by a 7.23% CAGR. Factors like rising cancer incidence, technological advancements in diagnostics, and the importance of early detection are pivotal for this expansion. The market is also fueled by a demand for personalized medicine and enhanced imaging services. Leading companies like Illumina, Abbott Laboratories, and Thermo Fisher Scientific aid this growth through innovations in g
The Lung Cancer Diagnostics Market is set to expand from US$ 21.74 billion in 2025 to US$ 38.00 billion by 2033, growing at a CAGR of 7.23%. Major growth drivers include increased public access facilities, rise in ambulance services, and higher prevalence of cardiac disorders. Advances in lung cancer detection techniques like chest X-rays, CT scans, and MRIs cater to the demand for early and accurate diagnoses, crucial for effective treatment. Market leaders such as Illumina, Abbott Laboratories
Klotho Neurosciences, Inc. ("Klotho" or the Company) announces the development of two genomics-based diagnostic tests that will be utilized in Klotho's clinical trials and to be provided as a service in the field of longevity and the understanding of the relationships between biological age and chronologic age.